The impact of tocilizumab on physical function and quality of life in patients with rheumatoid arthritis: A systematic literature review and interpretation

Open Access Rheumatology: Research and Reviews

Volumn 4, Issue , 2012, Pages 87-92

  Townes, Shatara V ^a   Furst, Daniel E ^a   Thenkondar, Anuradha ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SRI RAMACHANDRA UNIVERSITY   (India)

Author keywords

Quality of life; Randomized trials; Rheumatoid arthritis; Sleep; Tocilizumab

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; PLACEBO; TOCILIZUMAB;

DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; EPWORTH SLEEPINESS SCALE; FATIGUE; FUNCTIONAL STATUS; HUMAN; OUTCOME ASSESSMENT; QUALITY OF LIFE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SLEEP QUALITY; SYSTEMATIC REVIEW; TREATMENT DURATION;

EID: 84866170613     PISSN: None     EISSN: 1179156X     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58:2968-2980.
2. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatic arthritis (OPTION study): a double-blind, placebo-controlled, randomized trial. Lancet. 2008;371:987-997.
3. Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol. 2005;23:S14-S18.
4. Talamo J, Frater A, Gallivan S, Young A. Use of the short form 36 (SF36) for the health status measurement in rheumatoid arthritis. Br J Rheumatol. 1997;36:463-469.
5. Luo N, Chew LH, Fong KY, Koh DR, Ng SC, Yoon KH. Validity and reliability of the EQ-5D self-report questionnaire in Chinese-speaking patients with rheumatic diseases in Singapore. Ann Acad Med Singapore. 2003;32:685-690.
6. Calculating the US population-based EQ-5D Index Score. August 2005. Agency for Healthcare Research and Quality. Rockville, MD. http://www.ahrq.gov/rice/EQ5Dscore.htm. Accessed April 17, 2011.
7. Webster K, Cella D, Yost K. The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1:79.
8. Chandran V, Bhella S, Schentag C, Gladman DD. Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis. 2007;66:936-939.
9. FACIT. org [homepage on the Internet]. Available from: http://www.facit.org/FACITOrg/Questionnaires. Accessed April 17, 2011.
10. Buysse DJ, Hall ML, Strollo PJ, Kamarck TW, Owens J, Lee Laisze. Relationships between the Pittsburgh sleep quality index (PSQI), Epworth sleepiness scale (ESS), and clinical/polysomnographic measures in a community sample. J Clin Sleep Med. 2008;4:563-571.
11. Nishimoto N, Miyasaka N, Kamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19:12-19.
12. Maini RN, Taylor PC, Scechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54:2817-2829.
13. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69:88-96.
14. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biological: results from a 24-week multicenter randomized placebo-controlled trial. Ann Rheum Dis. 2008;67:1516-1523.
15. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162-1167.
16. Nishimoto N, Yosizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50:1716-1769.
17. Choy EH, Isenberg DA, Garrood T, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interlukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. 2002;46(12):3143-3150.
18. Khraishi M, Alten R, Gomez-Reino JJ, et al. Long-term efficacy of tocilizumab (TCZ) in patients with rheumatoid arthritis (RA) treated up to 3.7 years [abstract]. ACR. 2010:S760-S761.
19. Takeuchi T, Tanaka Y, Amano K, et al. Clinical, structural and functional remission in the treatment of rheumatoid arthritis with tocilizumab in daily clinical practice-REACTION-2 study [abstract]. ACR. 2010:S747.
20. Kremer JM, Furst DE, Burgos-Vargas R, et al. LITHE: Tocilizumab (TCZ) inhibits radiographic progression and improves physical function in rheumatoid arthritis (RA) patients (pts) at 3 years with maintenance of clinical efficacy over time [abstract]. Arthritis Rheum. 2011;63(3):609-621.
21. Jones G, Sebba A, Calvo A, et al. Efficacy of tocilizumab in patients with rheumatoid arthritis who had never been exposed to or had never failed methotrexate: analysis of up to 3 years of treatment in a long-term extension study [abstract]. Ann Rheum Dis. 2010;69:386.
22. Fragiadaki K, Sfikakis PP. EULAR. Effect of the first and second infusion of tocilizumab on sleep and daytime sleepiness in patients with active rheumatoid arthritis [abstract]. Ann Rheum Dis. 2010; 69:683.
23. Burmester G, Feist E, Kellner H, Braun J, Iking-Konert C, Rubbert-Roth A. Extended report: Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rhem Dis. 2011;70:755-759.